Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

(2020) William P. Tew et al.   JOURNAL OF CLINICAL ONCOLOGY

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

(2019) Andrea Wang-Gillam et al.   EUROPEAN JOURNAL OF CANCER

Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

(2019) Ashton A. Connor et al.   CANCER CELL

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

(2019) Talia Golan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

(2019) Samantha A. Armstrong et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative

(2018) Michael J. Pishvaian et al.   CLINICAL CANCER RESEARCH

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer

(2017) R Tyler Hillman et al.   JNCI-Journal of the National Cancer Institute

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

(2017) Helen Davies et al.   NATURE MEDICINE

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer

(2017) R Tyler Hillman et al.   JNCI-Journal of the National Cancer Institute

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

(2015) David Fogelman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

(2014) Eiji Kubota et al.   CELL CYCLE

Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis

(2014) H. Kim et al.   CLINICAL CANCER RESEARCH

Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients

(2013) Hee Sung Kim et al.   PATHOBIOLOGY